Descrizione Clinica
Diagnostics - diagnostics Screen drug test urine 5
SCREEN
DRUG TEST
URINA 5
Instructions for use for each combination of tests of the following drugs: amphetamine, metamphetamine, cocaine, marijuana and opioids.
Single-step test for the simultaneous qualitative determination of drugs and their metabolites in human urine.
PRECAUTIONS
Product not intended for medical or diagnostic use.
• Do not use beyond the expiry date.
• Store the reactive strip panel in the closed enclosure until use.
• All samples must be considered potentially dangerous and therefore must be manipulated with precautions of use relating to potentially infectious products.
• After use, the panel must be deleted according to the local rules in force.
Store in the closed enclosure at a temperature between 2° and 30°C.
The test strip panel is stable until the expiration date indicated on the package label.
The reactive strip panel must be kept in the closed enclosure until the time of use.
Don't freeze.
Do not use beyond expiration date.
PREVIOUS AND RIEPILOGO
Screening test for the simultaneous detection of several drugs.
The rapidity and sensitivity of immunological tests have led them to be considered the most accepted as screening tests in the urine for simultaneous drug research.
The monophase test strip panel (Urina) is a lateral flow immunochromatic test for qualitative determination of the following drugs without the help of tools.
This test only provides preliminary analytical data. More specific chemical methods must be used as confirmation of analytical result.
Preferential confirmation methods are considered for gaschromatography and mass spectrometry (GC/MS).
Any result for determining the presence of abuse drugs must be related to clinical considerations and professional judgment, especially when the preliminary result is positive.
Quick screening test of urine that does not require the use of special tools.
The test uses antibodies to selectively detect high levels of specific substances in human urine.
The time of stay is approximate for each substance as they vary according to the frequency of use, body mass, age, state of health, tolerance to the narcotic substances and the pH of urine.
It detects the presence of narcotic substances in urine only after their metabolization.
COCAINE (COC)
Cocaine is a powerful stimulant of the central nervous system as well as local anesthetic derived from the coca plant.
The substance is often self administered by inhalation or intravenous injection or by smoking the base substance.
AMFETAMINA (AMP)
Amphetamine is a substance also used for therapeutic purposes.
The substance is often self- administered by inhalation or ingestion.
High doses produce enhanced stimulation of the central nervous system and induce euphoria, vigile state, appetite reduction, sense of greater energy and strength.
Acute reactions produce anxiety, paranoia, hallucinations and psychotic behavior.
METAMFETAMINA (mAMP)
Metamfetamine is a powerful chemically related stimulant to amphetamine, but with a greater stimulation capacity of the central nervous system.
The substance is often self administered by inhalation, smoking or ingestion.
MARIJUANA (THC)
Tetrahydrocannabinol is the active ingredient of cannabis.
When smoked or taken orally, THC produces euphoria.
Regular consumers have short-term memory damage and learning delay, they can also have transient episodes of confusion and anxiety.
Relatively heavy long-term consumption may be associated with behavior disorders.
OPPIACEI (OPI)
The class of opioids refers to any substance derived from opium poppy, including natural compounds such as morphine, codeine and semisynthetic substances such as heroin.
Opiates act on pain control by depressing the central nervous system.
Astinence symptoms may include sweating, tremors, nausea and irritability.
Opiates can be taken orally or through intravenous, intramuscular and subcutaneous injection.
Consumers may also take the substance intravenously or through inhalation.
PRINCIPLE
The monophase test strip panel (Urina) is a rapid immunochromatic test based on the competitive binding principle.
Drugs that may be present in the urine sample compete with its conjugate for the same antibody binding sites.
During the test, a urine sample migrates by capillaries along the membrane.
A drug, if present in the urine sample, at a lower concentration than its cut-off, will not be able to saturate all particle binding sites related to the relative antibodies present in the strip.
Antibodies tied particles will be captured by the immobilized conjugate and a visible colored band will appear in the test band area of its strip.
The colored band will not form in its area if the drug level will be higher than its cut-off, as all related antibodies binding sites will be saturated.
A positive drug urine sample will not cause colored band formation due to drug competition, while a negative urine sample to the drug under examination or a sample containing a drug concentration lower than the cut-off will cause colored band formation in the specific test area.
As a procedure control, a colored band will appear in the relative area, indicating that a correct sample amount has been used and that the migration on the membrane occurred.
REASONS
Each strip of the panel contains monoclonal antibodies of rats linked to the particles and the corresponding.
The monophase test strip panel (Urina) is a conjugated lateral flow immunochromatic test for each drug.
Goat antibodies are used for control gang.
PRELIENT AND PREPARATION OF CHAMPIONS
Collect urine sample in a clean and dry container.
Urine samples collected at any time of the day can be used.
The urine samples with evident precipitation must be centrifuged, filtered or left to deposit so as to obtain a clear sample on which to test.
Urine samples can be stored at a temperature of 2-8°C at most for 48 hours.
For prolonged storage, samples can be frozen and stored at a temperature below -20°C.
Before using frozen samples it is necessary to make them defrost and homogenize them thoroughly.
PROCEDURE OF USE
1. Before opening the enclosure, bring it to room temperature.
Extract the product from the wrap and use it as soon as possible.
2. Remove the hood from the stripes. Dip the product vertically, towards the arrows, into the urine sample for at least 10/15 seconds. Dip the product to the level of the undulated rows on the strips but not above them.
3. Put the cap on the device and horizontally rest the product on a flat surface not absorbent. Read the result after 5 minutes. Do not interpret the result after 10 minutes.
INTERPRETATION OF RESULTS
Negative*: a coloured band appears in the control area (C) to a second in the reactive area (T) for each drug indicating a negative result. The negative result indicates that the drug concentration in the urine is below the cut-off level detectable for that specific drug.
*the color shade in the reactive zone (T) may vary, but it must be considered negative whenever a weak colored band appears.
Positive: a colored band appears in the control area (C) but not in the reactive area (T) for each drug indicating a positive result. The positive result indicates that the drug concentration in question in urine is higher than the cut-off level detectable for that specific drug.
Not valid: the control band (C) does not appear. The most plausible causes for the failure of the control band can be an insufficient sample volume or incorrect analytical process.
Recheck the process and repeat the test using a new panel. If the problem persists immediately interrupt the use of the kit and contact the local distributor.
If the test was positive, avoid aggressive behaviour and calmly seek dialogue with the person concerned.
Please be advised by your doctor, a psychologist or contact the competent service for your territory.
QUALITY CONTROL
The test includes an internal control system consisting of the red band that appears in the control area (C).
The appearance of this band confirms that the test was performed correctly with a sufficient sample volume, that the absorption of the membrane was adequate and the correct procedure.
Standard controls are not provided with the kit; however it is recommended to test positive and negative controls, such as good laboratory practice, to confirm the test procedure and verify the correct characteristics.
LIMITED
1. The single-phase test strip panel (Urina) provides only a qualitative preliminary analytical result. It is necessary to adopt a second analytical method. Preferential confirmation methods are considered for the gaschromatography and mass spectrometry (GC/MS) as recommended confirmation methods if the test is positive.
2. It is possible that technical or procedural errors, as well as interfering substances present in the urine sample, can cause incorrect results.
3. It is possible that adulterating substances, such as bleach and/or alumen present in the urine sample may cause incorrect results regardless of the analytical method used. If you suspect the presence of such substances, the test must be repeated with another urine sample.
4. A positive result indicates the presence of drugs or metabolites but not the level of intoxication the way of administration or concentration in urine.
5. A negative result does not necessarily mean that the urine sample is drug-free. A negative result can be obtained when the drug is present but at a lower concentration than the cut-off level of the test.
6. The test is not able to distinguish between the drug and a drug containing the same positive false substance can be caused by certain drugs.
FORM
• 1 urine container.
• 1 Drug Test Urina 5.
• 1 leaflet.
Single-step test for the simultaneous qualitative determination of drugs and their metabolites in human urine.
PRECAUTIONS
Product not intended for medical or diagnostic use.
• Do not use beyond the expiry date.
• Store the reactive strip panel in the closed enclosure until use.
• All samples must be considered potentially dangerous and therefore must be manipulated with precautions of use relating to potentially infectious products.
• After use, the panel must be deleted according to the local rules in force.
Store in the closed enclosure at a temperature between 2° and 30°C.
The test strip panel is stable until the expiration date indicated on the package label.
The reactive strip panel must be kept in the closed enclosure until the time of use.
Don't freeze.
Do not use beyond expiration date.
PREVIOUS AND RIEPILOGO
Screening test for the simultaneous detection of several drugs.
The rapidity and sensitivity of immunological tests have led them to be considered the most accepted as screening tests in the urine for simultaneous drug research.
The monophase test strip panel (Urina) is a lateral flow immunochromatic test for qualitative determination of the following drugs without the help of tools.
| Test | Calibrator | Cut-off (ng/ml) |
| Cocaine (COC) | benzoilecgoni | 300 |
| Amphetamine (AMP) | D-amfetamine | 1.000 |
| Metamfetamine (mAMP) | D-methylamine | 1.000 |
| Marijuana (THC) | 11-nor-Δ9-THC-9 COOH | 50 |
| Opioids (OPI) | morphine | 2.000 |
This test only provides preliminary analytical data. More specific chemical methods must be used as confirmation of analytical result.
Preferential confirmation methods are considered for gaschromatography and mass spectrometry (GC/MS).
Any result for determining the presence of abuse drugs must be related to clinical considerations and professional judgment, especially when the preliminary result is positive.
Quick screening test of urine that does not require the use of special tools.
The test uses antibodies to selectively detect high levels of specific substances in human urine.
The time of stay is approximate for each substance as they vary according to the frequency of use, body mass, age, state of health, tolerance to the narcotic substances and the pH of urine.
It detects the presence of narcotic substances in urine only after their metabolization.
COCAINE (COC)
Cocaine is a powerful stimulant of the central nervous system as well as local anesthetic derived from the coca plant.
The substance is often self administered by inhalation or intravenous injection or by smoking the base substance.
AMFETAMINA (AMP)
Amphetamine is a substance also used for therapeutic purposes.
The substance is often self- administered by inhalation or ingestion.
High doses produce enhanced stimulation of the central nervous system and induce euphoria, vigile state, appetite reduction, sense of greater energy and strength.
Acute reactions produce anxiety, paranoia, hallucinations and psychotic behavior.
METAMFETAMINA (mAMP)
Metamfetamine is a powerful chemically related stimulant to amphetamine, but with a greater stimulation capacity of the central nervous system.
The substance is often self administered by inhalation, smoking or ingestion.
MARIJUANA (THC)
Tetrahydrocannabinol is the active ingredient of cannabis.
When smoked or taken orally, THC produces euphoria.
Regular consumers have short-term memory damage and learning delay, they can also have transient episodes of confusion and anxiety.
Relatively heavy long-term consumption may be associated with behavior disorders.
OPPIACEI (OPI)
The class of opioids refers to any substance derived from opium poppy, including natural compounds such as morphine, codeine and semisynthetic substances such as heroin.
Opiates act on pain control by depressing the central nervous system.
Astinence symptoms may include sweating, tremors, nausea and irritability.
Opiates can be taken orally or through intravenous, intramuscular and subcutaneous injection.
Consumers may also take the substance intravenously or through inhalation.
PRINCIPLE
The monophase test strip panel (Urina) is a rapid immunochromatic test based on the competitive binding principle.
Drugs that may be present in the urine sample compete with its conjugate for the same antibody binding sites.
During the test, a urine sample migrates by capillaries along the membrane.
A drug, if present in the urine sample, at a lower concentration than its cut-off, will not be able to saturate all particle binding sites related to the relative antibodies present in the strip.
Antibodies tied particles will be captured by the immobilized conjugate and a visible colored band will appear in the test band area of its strip.
The colored band will not form in its area if the drug level will be higher than its cut-off, as all related antibodies binding sites will be saturated.
A positive drug urine sample will not cause colored band formation due to drug competition, while a negative urine sample to the drug under examination or a sample containing a drug concentration lower than the cut-off will cause colored band formation in the specific test area.
As a procedure control, a colored band will appear in the relative area, indicating that a correct sample amount has been used and that the migration on the membrane occurred.
REASONS
Each strip of the panel contains monoclonal antibodies of rats linked to the particles and the corresponding.
The monophase test strip panel (Urina) is a conjugated lateral flow immunochromatic test for each drug.
Goat antibodies are used for control gang.
PRELIENT AND PREPARATION OF CHAMPIONS
Collect urine sample in a clean and dry container.
Urine samples collected at any time of the day can be used.
The urine samples with evident precipitation must be centrifuged, filtered or left to deposit so as to obtain a clear sample on which to test.
Urine samples can be stored at a temperature of 2-8°C at most for 48 hours.
For prolonged storage, samples can be frozen and stored at a temperature below -20°C.
Before using frozen samples it is necessary to make them defrost and homogenize them thoroughly.
PROCEDURE OF USE
1. Before opening the enclosure, bring it to room temperature.
Extract the product from the wrap and use it as soon as possible.
2. Remove the hood from the stripes. Dip the product vertically, towards the arrows, into the urine sample for at least 10/15 seconds. Dip the product to the level of the undulated rows on the strips but not above them.
3. Put the cap on the device and horizontally rest the product on a flat surface not absorbent. Read the result after 5 minutes. Do not interpret the result after 10 minutes.
INTERPRETATION OF RESULTS
Negative*: a coloured band appears in the control area (C) to a second in the reactive area (T) for each drug indicating a negative result. The negative result indicates that the drug concentration in the urine is below the cut-off level detectable for that specific drug.
*the color shade in the reactive zone (T) may vary, but it must be considered negative whenever a weak colored band appears.
Positive: a colored band appears in the control area (C) but not in the reactive area (T) for each drug indicating a positive result. The positive result indicates that the drug concentration in question in urine is higher than the cut-off level detectable for that specific drug.
Not valid: the control band (C) does not appear. The most plausible causes for the failure of the control band can be an insufficient sample volume or incorrect analytical process.
Recheck the process and repeat the test using a new panel. If the problem persists immediately interrupt the use of the kit and contact the local distributor.
If the test was positive, avoid aggressive behaviour and calmly seek dialogue with the person concerned.
Please be advised by your doctor, a psychologist or contact the competent service for your territory.
QUALITY CONTROL
The test includes an internal control system consisting of the red band that appears in the control area (C).
The appearance of this band confirms that the test was performed correctly with a sufficient sample volume, that the absorption of the membrane was adequate and the correct procedure.
Standard controls are not provided with the kit; however it is recommended to test positive and negative controls, such as good laboratory practice, to confirm the test procedure and verify the correct characteristics.
LIMITED
1. The single-phase test strip panel (Urina) provides only a qualitative preliminary analytical result. It is necessary to adopt a second analytical method. Preferential confirmation methods are considered for the gaschromatography and mass spectrometry (GC/MS) as recommended confirmation methods if the test is positive.
2. It is possible that technical or procedural errors, as well as interfering substances present in the urine sample, can cause incorrect results.
3. It is possible that adulterating substances, such as bleach and/or alumen present in the urine sample may cause incorrect results regardless of the analytical method used. If you suspect the presence of such substances, the test must be repeated with another urine sample.
4. A positive result indicates the presence of drugs or metabolites but not the level of intoxication the way of administration or concentration in urine.
5. A negative result does not necessarily mean that the urine sample is drug-free. A negative result can be obtained when the drug is present but at a lower concentration than the cut-off level of the test.
6. The test is not able to distinguish between the drug and a drug containing the same positive false substance can be caused by certain drugs.
FORM
• 1 urine container.
• 1 Drug Test Urina 5.
• 1 leaflet.
